Loading...
01/11 03:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The financial performance shows a significant revenue decline and increased net losses, primarily due to the absence of milestone payments. Despite positive preclinical study results and ongoing partnerships, the lack of immediate new agreements and the focus on securing non-dilutive cash suggest operational and funding challenges. The Q&A section reveals uncertainty about future agreements, which could unsettle investors. The company's operational efficiency improvements are overshadowed by financial struggles, leading to a negative sentiment likely affecting the stock price in the short term.
GAAP Revenues Q3 2024 $4,000 compared to $43,000 for Q3 2023, a decrease of $39,000 (90.7% decrease). The decrease is mainly related to no deliveries planned or made to CollPlant's largest customer.
GAAP Revenues 9M 2024 $351,000 compared to $10.7 million for 9M 2023, a decrease of $10.35 million (96.7% decrease). The decrease is primarily due to a $10 million milestone payment received in 2023 from the AbbVie agreement.
GAAP Cost of Revenues Q3 2024 $272,000 compared to $278,000 in Q3 2023, a decrease of $6,000 (2.2% decrease).
GAAP Cost of Revenues 9M 2024 $1.4 million compared to $1.2 million for 9M 2023, an increase of $200,000 (16.7% increase). The increase is mainly due to $452,000 in inventory impairments, offset by $308,000 in royalty expenses.
GAAP Gross Loss Q3 2024 $268,000 compared to $235,000 in Q3 2023, an increase of $33,000 (14.0% increase).
GAAP Gross Loss 9M 2024 $1 million compared to a gross profit of $9.4 million for 9M 2023, a decrease of $10.4 million (110.6% decrease). This significant change is attributed to the milestone payment received in 2023.
GAAP Operating Expenses Q3 2024 $4.3 million compared to $4.4 million in Q3 2023, a decrease of $100,000 (2.3% decrease). The decrease is mainly due to a reduction in employee salaries and share-based compensation.
GAAP Operating Expenses 9M 2024 $12.3 million compared to $11.9 million for 9M 2023, an increase of $400,000 (3.4% increase). The increase is primarily related to development activities in the breast implants project.
GAAP Financial Income Net Q3 2024 $216,000 compared to $225,000 in Q3 2023, a decrease of $9,000 (4.0% decrease).
GAAP Financial Income Net 9M 2024 $546,000 compared to $114,000 for 9M 2023, an increase of $432,000 (378.9% increase). The increase is due to interest received from short-term cash deposits and exchange rate differences.
GAAP Net Loss Q3 2024 $4.3 million or $0.38 basic loss per share compared to a net loss of $4.4 million or $0.38 basic loss per share for Q3 2023, a decrease of $100,000 (2.3% decrease).
Non-GAAP Net Loss Q3 2024 $3.8 million or $0.33 loss per share compared to a net loss of $4 million or $0.35 basic loss per share for Q3 2023, a decrease of $200,000 (5.0% decrease).
GAAP Net Loss 9M 2024 $12.7 million or $1.11 basic loss per share compared to a net loss of $2.3 million or $0.20 basic loss per share for 9M 2023, an increase of $10.4 million (452.2% increase). This increase is primarily due to the milestone payment received in 2023.
Non-GAAP Net Loss 9M 2024 $11.5 million or $1 loss per share compared to a net loss of $1.2 million or $0.11 basic loss per share for 9M 2023, an increase of $10.3 million (858.3% increase).
Cash and Cash Equivalents $15.4 million as of September 30, 2024.
Cash Used in Operating Activities 9M 2024 $10.6 million compared to $418,000 for 9M 2023, an increase of $10.2 million (2435.1% increase).
Cash Used in Investing Activities 9M 2024 $481,000 compared to $784,000 for 9M 2023, a decrease of $303,000 (38.7% decrease).
Cash Provided by Financing Activities 9M 2024 $9,000 compared to $1.1 million for 9M 2023, a decrease of $1.091 million (99.2% decrease). This decrease is due to the absence of proceeds from the exercise of warrants in the current period.
Regenerative Breast Implant Program: Advancement of preclinical study for 200cc breast implants using proprietary rhCollagen-based bioinks. Study shows good results with significant implant vascularization and rapid tissue ingrowth.
Dermal and Soft Tissue Filler Product: Collaboration with AbbVie focused on developing a filler that offers wrinkle filling and skin tissue regeneration properties.
Global Breast Implant Market: Estimated at $3 billion, projected to grow to approximately $6.5 billion by 2033.
Filler Market: Valued at approximately $5.5 billion, expected to grow by 10% annually.
Operational Efficiencies: Streamlining operations and reducing annual burn rate.
Collaboration Partnerships: Prioritizing securing non-dilutive cash through additional collaborations.
Future Goals: Focus on advancing dermal filler program, generating safety and efficacy data for breast implants, and forming collaborations for rhCollagen and bioink technologies.
Regulatory Issues: The company faces regulatory challenges in developing new medical products, particularly in ensuring that their implants do not induce immune responses and are safe for patients.
Competitive Pressures: CollPlant operates in a highly competitive market for regenerative medicine and aesthetics, with significant interest from other companies in their collagen technology.
Supply Chain Challenges: There are potential supply chain risks related to the production and delivery of rhCollagen, as evidenced by the decrease in revenues due to no planned deliveries to their largest customer in Q3 2024.
Economic Factors: The company is affected by economic conditions that influence the demand for aesthetic and reconstructive procedures, which are projected to grow but may be impacted by broader economic trends.
Financial Performance: CollPlant reported a significant decrease in revenues from $10.7 million in the first nine months of 2023 to $351,000 in the same period of 2024, primarily due to a lack of milestone payments and customer deliveries.
Cash Burn Rate: The company is focused on reducing its annual burn rate and securing non-dilutive cash through collaborations, indicating financial sustainability challenges.
Regenerative Breast Implant Program: Advancing preclinical study with 200cc commercial-sized breast implants using proprietary rhCollagen-based bioinks. Study shows good results with significant implant vascularization and rapid tissue ingrowth.
Collaboration with AbbVie: Focused on developing a dermal and soft tissue filler product for the medical aesthetics market, valued at approximately $5.5 billion, expected to grow 10% annually.
Cash Management: Prioritizing securing non-dilutive cash through collaboration partnerships and streamlining operations to reduce annual burn rate.
Market Potential: Global breast implant market estimated at $3 billion, projected to grow to $6.5 billion by 2033.
Future Agreements: Management aims to sign another agreement regarding collagen technology during 2025.
Financial Outlook: Cash and cash equivalents as of September 30, 2024, were $15.4 million, expected to satisfy operational requirements until at least the end of 2025.
Revenue Expectations: GAAP revenues for Q3 2024 were $4,000, a decrease from $43,000 in Q3 2023, with expectations to supply rhCollagen to a major customer in December 2024.
Operating Expenses: GAAP operating expenses for Q3 2024 were $4.3 million, a slight decrease from $4.4 million in Q3 2023, with a focus on development activities for breast implants.
Shareholder Return Plan: CollPlant is prioritizing securing non-dilutive cash through collaboration partnerships to support clinical testing of their regenerative breast implants and dermal filler products.
Cash Position: As of September 30, 2024, CollPlant had cash and cash equivalents of $15.4 million, which is expected to sustain operations until at least the end of 2025.
The company's financial performance shows a significant decline in revenue and increased cash burn, despite a reduced net loss. The Q&A section highlights uncertainties with AbbVie milestones and unclear management responses, adding to investor concerns. Additionally, the cash runway suggests potential liquidity issues. These factors, combined with competitive pressures and regulatory risks, likely lead to a negative stock price reaction.
Despite some positive developments, such as the collaboration with AbbVie and cash management strategies, the overall financial performance is weak, with declining revenues and increased net losses. The lack of clear guidance from management, combined with regulatory risks and competitive market pressures, further contribute to a negative sentiment. The Q&A session highlighted uncertainties about future milestone payments and revenue streams, adding to investor concerns. These factors suggest a negative stock price reaction in the near term.
The earnings call reveals a mixed picture: while there are some positives, such as a payment from AbbVie and reduced operating expenses, the financial performance is concerning. Revenue has significantly decreased, there's a high cash burn rate, and the net loss has increased. The absence of detailed guidance and potential regulatory and competitive risks further weigh negatively. The market reaction is likely to be negative as the financial outlook appears weak, with uncertainties around future revenue and milestone payments.
The financial performance shows a significant revenue decline and increased net losses, primarily due to the absence of milestone payments. Despite positive preclinical study results and ongoing partnerships, the lack of immediate new agreements and the focus on securing non-dilutive cash suggest operational and funding challenges. The Q&A section reveals uncertainty about future agreements, which could unsettle investors. The company's operational efficiency improvements are overshadowed by financial struggles, leading to a negative sentiment likely affecting the stock price in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
